<DOC>
	<DOC>NCT00139334</DOC>
	<brief_summary>The main objective of this study is to provide immunogenicity data for GSK Biologicals' HRV vaccine when co-administered with OPV or when given alone (HRV vaccine dose given 15 days after the OPV dose).</brief_summary>
	<brief_title>A Study to Test 2 Doses of the HRV Vaccine Given With or Without OPV in Healthy Infants in Bangladesh</brief_title>
	<detailed_description>"The study will have four groups: Group HRV + OPV, Group HRV alone, Group Placebo + OPV and Group Placebo alone. Two-dose immunisation will be administered in healthy infants at approximately 12 and 16 weeks of age. Immunogenicity, reactogenicity and safety relative to the placebo will also be evaluated. Treatment allocation: randomized (2:2:1:1). Routine EPI vaccines should be administered during the study following the EPI recommendation in Bangladesh."</detailed_description>
	<mesh_term>Rotavirus Infections</mesh_term>
	<criteria>Inclusion criteria: Healthy infants aged 6 weeksÂ±1 at first study vaccination. Exclusion criteria: Malnutrition, no history of rotavirus gastroenteritis, allergic disease or chronic gastrointestinal disease, not received protocolprohibited treatment.</criteria>
	<gender>All</gender>
	<minimum_age>5 Weeks</minimum_age>
	<maximum_age>7 Weeks</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>